Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?
Koletsa T, Kotoula V, Koliou GA, Manousou K, Chrisafi S, Zagouri F, Sotiropoulou M, Pentheroudakis G, Papoudou-Bai A, Christodoulou C, Xepapadakis G, Zografos G, Petraki K, Pazarli E, Koutras A, Kourea HP, Bafaloukos D, Chatzopoulos K, Iliadis A, Markopoulos C, Venizelos V, Arnogiannaki N, Kalogeras KT, Kostopoulos I, Gogas H, Fountzilas G.
Koletsa T, et al. Among authors: chrisafi s.
Cancer Immunol Immunother. 2020 Aug;69(8):1549-1564. doi: 10.1007/s00262-020-02557-0. Epub 2020 Apr 18.
Cancer Immunol Immunother. 2020.
PMID: 32303794
Free PMC article.